Vertex is expanding beyond its cystic fibrosis franchise.
Private equity and corporate ownership are driving up prices and forcing people to make awful choices about their animal ...
Lund, Sweden - 12 October 2026 - Camurus (NASDAQ STO: CAMX) today announced that Health Canada has issued a Notice of Compliance (NOC) for Oczyesa ® XR, octreotide subcutaneous depot, for maintenance ...
Vertex Pharmaceuticals is showing that it isn't a one-trick pony.
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has spent years building a highly profitable cystic fibrosis franchise. Now ...
A new Finnish nationwide cohort study found that patients with acromegaly had about 1.6-fold higher cardiovascular morbidity than matched control individuals from the general population. The risk was ...
Global Somatostatin Analogs Market size is expected to be worth around US$ 18.6 Billion by 2034 from US$ 5.3 Billion in 2024.
The trial also met both secondary endpoints; FDA accepted Vertex’s application for potential accelerated approval, with a Nov ...
Tumor Load and Presentation: Data demonstrated a cohort dominated by macroadenomas (94.0%, including 15.4% giant adenomas ≥40 ...
A Bulgarian study combining systematic review with real-world analysis reveals that drug-related problems in geriatric ...
A minireview reports that cardiomyocyte-specific loss of the Bmal1 clock gene increases cardiac growth hormone sensitivity in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results